Expression of SART3 tumor-rejection antigen in gastric cancers.
We previously reported SART3 as a tumor-rejection antigen recognized by histocompatibility leukocyte antigen (HLA)-A24-restricted cytotoxic T lymphocytes (CTLs). In this study, we investigated the expression of the SART3 antigen in gastric cancers, as a candidate for use in specific immunotherapy. The SART3 antigen was detected in 9 of 10 (90%) gastric cancer cell lines, 35 of 52 (67.3%) gastric cancer tissues, and 0 of 20 non-tumorous gastric tissues. SART3-derived peptides corresponding to positions 109- 118 and 315-323 induced HLA-A24-restricted and tumor-specific CTLs from peripheral blood mononuclear cells (PBMCs) of gastric cancer patients. These peptide-induced CTLs recognized HLA-A24(+) SART3(+) gastric cancer cells, but not HLA-A24(+) SART3(-) or HLA-A24(-) SART3(+) gastric cancer cells. Therefore, the SART3 peptides could be useful in specific immunotherapy of gastric cancer patients.
Niiya
F
F
Departments of Immunology and Surgery, Kurume University School of Medicine, Asahi-machi, Kurume, 830-0011, Japan.
Nishizaka
S
S
Matsunaga
K
K
Koufuji
K
K
Mori
M
M
Katai
H
H
Yamana
H
H
Itoh
K
K
D000230:Adenocarcinoma / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000032:analysis*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002467:Cell Nucleus / Q000276:immunology; D003600:Cytosol / Q000276:immunology; D006801:Humans; D008213:Lymphocyte Activation; D013270:Stomach / Q000276:immunology; D013274:Stomach Neoplasms / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm